RU2011125306A - Праймирование иммунного ответа - Google Patents
Праймирование иммунного ответа Download PDFInfo
- Publication number
- RU2011125306A RU2011125306A RU2011125306/10A RU2011125306A RU2011125306A RU 2011125306 A RU2011125306 A RU 2011125306A RU 2011125306/10 A RU2011125306/10 A RU 2011125306/10A RU 2011125306 A RU2011125306 A RU 2011125306A RU 2011125306 A RU2011125306 A RU 2011125306A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- acid construct
- invariant chain
- peptide
- protein
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title claims 14
- 230000037452 priming Effects 0.000 title claims 4
- 108020004707 nucleic acids Proteins 0.000 claims abstract 34
- 102000039446 nucleic acids Human genes 0.000 claims abstract 34
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 34
- 108010028930 invariant chain Proteins 0.000 claims abstract 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract 25
- 235000018102 proteins Nutrition 0.000 claims abstract 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract 22
- 230000000890 antigenic effect Effects 0.000 claims abstract 18
- 125000000539 amino acid group Chemical group 0.000 claims abstract 13
- 239000012634 fragment Substances 0.000 claims abstract 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 4
- 235000004279 alanine Nutrition 0.000 claims abstract 4
- 235000001014 amino acid Nutrition 0.000 claims abstract 4
- 150000001413 amino acids Chemical class 0.000 claims abstract 4
- 229940022399 cancer vaccine Drugs 0.000 claims abstract 2
- 229930182817 methionine Natural products 0.000 claims abstract 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims abstract 2
- 230000001419 dependent effect Effects 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 229960005486 vaccine Drugs 0.000 claims 7
- 239000000969 carrier Substances 0.000 claims 5
- 125000002091 cationic group Chemical group 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 239000003981 vehicle Substances 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- -1 BCL-XL Proteins 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 102000043276 Oncogene Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 102000007327 Protamines Human genes 0.000 claims 1
- 108010007568 Protamines Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108020005202 Viral DNA Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 229920006317 cationic polymer Polymers 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 244000052637 human pathogen Species 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229920000083 poly(allylamine) Polymers 0.000 claims 1
- 229920000962 poly(amidoamine) Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229940048914 protamine Drugs 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000005829 trimerization reaction Methods 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801638 | 2008-11-21 | ||
| DKPA200801638 | 2008-11-21 | ||
| PCT/DK2009/050310 WO2010057501A1 (en) | 2008-11-21 | 2009-11-20 | Priming of an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017138373A Division RU2017138373A (ru) | 2008-11-21 | 2009-11-20 | Праймирование иммунного ответа |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011125306A true RU2011125306A (ru) | 2012-12-27 |
Family
ID=40823418
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011125306/10A RU2011125306A (ru) | 2008-11-21 | 2009-11-20 | Праймирование иммунного ответа |
| RU2017138373A RU2017138373A (ru) | 2008-11-21 | 2009-11-20 | Праймирование иммунного ответа |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017138373A RU2017138373A (ru) | 2008-11-21 | 2009-11-20 | Праймирование иммунного ответа |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20110293704A1 (enExample) |
| EP (3) | EP3552622A3 (enExample) |
| JP (4) | JP2012509071A (enExample) |
| CN (3) | CN107090472A (enExample) |
| AU (1) | AU2009317691A1 (enExample) |
| BR (1) | BRPI0921927B8 (enExample) |
| CA (1) | CA2743229A1 (enExample) |
| CY (1) | CY1122117T1 (enExample) |
| DK (1) | DK2865387T3 (enExample) |
| ES (1) | ES2743677T3 (enExample) |
| HK (1) | HK1209645A1 (enExample) |
| HR (1) | HRP20191594T1 (enExample) |
| HU (1) | HUE045093T2 (enExample) |
| IL (4) | IL212914A0 (enExample) |
| LT (1) | LT2865387T (enExample) |
| PL (1) | PL2865387T3 (enExample) |
| PT (1) | PT2865387T (enExample) |
| RU (2) | RU2011125306A (enExample) |
| SI (1) | SI2865387T1 (enExample) |
| WO (1) | WO2010057501A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2918452T3 (es) | 2007-02-19 | 2022-07-15 | Marine Polymer Tech Inc | Composiciones hemostáticas y regímenes terapéuticos |
| CA2800424C (en) * | 2010-06-04 | 2018-10-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | B1,2 cyclic beta glucan compound for use to enhance adaptive immunity by activation of dendritic cells |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| US20140348863A1 (en) * | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| JP6263474B2 (ja) | 2011-12-07 | 2018-01-17 | シンガポール ボリション ピーティーイー リミテッド | ヌクレオソームアダクト検出法 |
| EP2877205A4 (en) * | 2012-07-26 | 2016-04-06 | Jackson H M Found Military Med | VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY |
| WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| HK1220626A1 (zh) | 2013-03-15 | 2017-05-12 | The Centre For Drug Research And Development | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
| US10576143B2 (en) | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| SG10201801428RA (en) | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
| MX2016008448A (es) * | 2013-12-27 | 2017-01-09 | Zymeworks Inc | Conjugados de var2csa-farmaco. |
| ES2905569T3 (es) | 2014-09-17 | 2022-04-11 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos y métodos para utilizarlos |
| WO2017025782A1 (en) | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
| CN108601820A (zh) * | 2015-10-12 | 2018-09-28 | 南托米克斯有限责任公司 | 用于病毒癌症新表位的组合物和方法 |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| MX2019002178A (es) * | 2016-08-23 | 2019-09-18 | Glaxosmithkline Biologicals Sa | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| US20200230220A1 (en) * | 2017-07-12 | 2020-07-23 | Nouscom Ag | Neoantigen vaccine composition for treatment of cancer |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| CN111670046B (zh) * | 2017-11-03 | 2024-11-08 | Nouscom股份公司 | 疫苗的t细胞增强剂 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| CN108285885A (zh) * | 2017-12-28 | 2018-07-17 | 中国农业大学 | 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用 |
| MX2020013553A (es) | 2018-06-12 | 2021-02-26 | Glaxosmithkline Biologicals Sa | Polinucleotidos y polipeptidos de adenovirus. |
| US12576143B2 (en) | 2018-10-19 | 2026-03-17 | Nouscom Ag | Teleost invariant chain cancer vaccine |
| EP3897846A1 (en) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| RU2725493C2 (ru) * | 2018-12-28 | 2020-07-02 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора |
| BR112021017584A2 (pt) | 2019-03-05 | 2021-11-09 | Glaxosmithkline Biologicals Sa | Regime e composições de imunização contra hepatite b |
| CN111729093B (zh) * | 2020-06-29 | 2022-05-24 | 南京超维景生物科技有限公司 | 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法 |
| EP4137153A1 (en) | 2021-08-18 | 2023-02-22 | Sirion Biotech GmbH | Therapeutic papilloma virus vaccines |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
| CN117844685A (zh) * | 2023-12-19 | 2024-04-09 | 佛山科学技术学院 | 一株维氏气单胞菌及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US587673A (en) | 1897-08-03 | higgins | ||
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| JP2682061B2 (ja) | 1988-10-07 | 1997-11-26 | 藤沢薬品工業株式会社 | ペプチドの分子内ジスルフィド結合の形成法 |
| US5559028A (en) * | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
| US5876735A (en) | 1994-04-22 | 1999-03-02 | Corixa Corporation | Methods for enhancement of protective immune responses |
| AU7690896A (en) * | 1995-09-14 | 1997-04-01 | Universitat Tubingen | Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide |
| AU3307497A (en) * | 1996-06-26 | 1998-01-14 | Antigen Express, Inc. | Immunotherapy by modulation of antigen presentation |
| US6534482B1 (en) * | 1998-05-13 | 2003-03-18 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| US20030235594A1 (en) * | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US6432409B1 (en) * | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
| GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| SI1957528T1 (sl) | 2005-11-30 | 2013-02-28 | University Of Copenhagen | Nukleotidno cepivo |
| US20080095798A1 (en) * | 2006-10-18 | 2008-04-24 | Robert Humphreys | Ii-key enhanced vaccine potency |
| US9085638B2 (en) * | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
| JP5707326B2 (ja) * | 2008-09-02 | 2015-04-30 | アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． | ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法 |
-
2009
- 2009-11-20 SI SI200931996T patent/SI2865387T1/sl unknown
- 2009-11-20 HU HUE15152408A patent/HUE045093T2/hu unknown
- 2009-11-20 LT LTEP15152408.9T patent/LT2865387T/lt unknown
- 2009-11-20 BR BRPI0921927A patent/BRPI0921927B8/pt active Search and Examination
- 2009-11-20 ES ES15152408T patent/ES2743677T3/es active Active
- 2009-11-20 CN CN201710007117.6A patent/CN107090472A/zh active Pending
- 2009-11-20 PL PL15152408T patent/PL2865387T3/pl unknown
- 2009-11-20 EP EP19173464.9A patent/EP3552622A3/en active Pending
- 2009-11-20 AU AU2009317691A patent/AU2009317691A1/en not_active Abandoned
- 2009-11-20 US US13/129,857 patent/US20110293704A1/en not_active Abandoned
- 2009-11-20 CA CA2743229A patent/CA2743229A1/en active Pending
- 2009-11-20 RU RU2011125306/10A patent/RU2011125306A/ru unknown
- 2009-11-20 PT PT15152408T patent/PT2865387T/pt unknown
- 2009-11-20 RU RU2017138373A patent/RU2017138373A/ru not_active Application Discontinuation
- 2009-11-20 DK DK15152408.9T patent/DK2865387T3/da active
- 2009-11-20 JP JP2011536741A patent/JP2012509071A/ja active Pending
- 2009-11-20 WO PCT/DK2009/050310 patent/WO2010057501A1/en not_active Ceased
- 2009-11-20 EP EP15152408.9A patent/EP2865387B1/en active Active
- 2009-11-20 CN CN2009801549244A patent/CN102292102A/zh active Pending
- 2009-11-20 CN CN201410485599.2A patent/CN104404068A/zh active Pending
- 2009-11-20 EP EP09760468A patent/EP2355842A1/en not_active Withdrawn
-
2011
- 2011-05-16 IL IL212914A patent/IL212914A0/en unknown
-
2014
- 2014-06-16 IL IL233176A patent/IL233176A0/en unknown
- 2014-06-16 IL IL233174A patent/IL233174A0/en unknown
- 2014-06-16 IL IL233175A patent/IL233175A0/en unknown
- 2014-09-10 US US14/482,452 patent/US20150056227A1/en not_active Abandoned
- 2014-11-07 JP JP2014226711A patent/JP2015061530A/ja active Pending
-
2015
- 2015-10-28 HK HK15110589.9A patent/HK1209645A1/en unknown
-
2017
- 2017-01-26 JP JP2017011749A patent/JP2017131220A/ja active Pending
- 2017-04-25 US US15/496,045 patent/US20170290898A1/en not_active Abandoned
-
2019
- 2019-05-15 JP JP2019091809A patent/JP6825036B2/ja active Active
- 2019-09-02 CY CY20191100920T patent/CY1122117T1/el unknown
- 2019-09-04 HR HRP20191594 patent/HRP20191594T1/hr unknown
-
2021
- 2021-06-17 US US17/350,971 patent/US20210386842A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017138373A (ru) | Праймирование иммунного ответа | |
| JP2012509071A5 (enExample) | ||
| CN107050440B (zh) | 疫苗组合物和其使用方法 | |
| Zeng et al. | Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy | |
| RU2712743C2 (ru) | Вакцина против бешенства | |
| US9770506B2 (en) | Adjuvant compound | |
| JP2022017499A (ja) | 治療用抗癌ネオエピトープワクチン | |
| US20180000912A1 (en) | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity | |
| EP3452086A1 (en) | Influenza mrna vaccines | |
| CA3036742A1 (en) | Modified vsv-g and vaccines thereof | |
| US20230355733A1 (en) | APC targeting units for immunotherapy | |
| Mbatha et al. | Future prospects in mRNA vaccine development | |
| Chamarthy et al. | A cationic peptide consists of ornithine and histidine repeats augments gene transfer in dendritic cells | |
| Kanazawa et al. | Enhancement of gene transfection into human dendritic cells using cationic PLGA nanospheres with a synthesized nuclear localization signal | |
| CN118576725A (zh) | 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用 | |
| CN118005805A (zh) | 基于铁蛋白合理设计的具有抗原、siRNA共递送的可增强机体免疫的纳米疫苗 | |
| ATE295419T1 (de) | Regulatorische sequenz zur spezifischen expression in dendritischen zellen und deren anwendungen | |
| Tockary et al. | Tethering designer short double-stranded RNA to mRNA for co-delivery of molecularly-targeted adjuvants and antigens towards cancer vaccination | |
| CN120248078B (zh) | 一种基于arc蛋白的修饰多肽及其作为核酸递送载体的应用 | |
| Tockary et al. | Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment | |
| WO2025027077A1 (en) | Agents and methods for targeted delivery of immune effector cells | |
| CN119432917A (zh) | 一种靶向外周免疫组织的基因免疫载体及其应用 |